Cancer Treatment Patent - Two-Part Treatment Regime
Summary
The USPTO published patent application US20260091097A1 for a two-part cancer treatment regime involving antigen-specific T cell therapy followed by inflammation-inducing treatment. The application, filed on April 18, 2025, covers methods of treating cancer using sequential administration of treatments to generate tumor-specific immune responses. Inventors include Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, and others.
What changed
The USPTO published a patent application covering methods of treating cancer using a two-part treatment regime. Part one involves providing antigen-specific CD4+ and/or CD8+ T cells to a subject, while part two induces systemic and/or tumor-specific inflammation after a time interval. The application includes 15 named inventors and covers various compositions including viral vectors, T cells, and immunomodulatory compounds.
This is a patent application publication, not a granted patent or regulatory requirement. Pharmaceutical companies and researchers developing immunotherapy treatments should review the claims for potential licensing considerations or freedom-to-operate analysis. No compliance deadlines or regulatory actions are associated with this publication.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMBINATION TREATMENT REGIMES FOR TREATING CANCER
Application US20260091097A1 Kind: A1 Apr 02, 2026
Inventors
Geoffrey Martin Lynn, Christopher Martin O'Brien Garliss, Andrew Scott Ishizuka, Faezzah Baharom, Robert Alan Seder, Ramiro Andrei Ramirez-Valdez
Abstract
The present disclosure relates to methods of treating cancer in subjects by a two-part treatment regime comprising a first treatment that provides antigen-specific CD4+ and/or CD8+ T cells in the subject and a second treatment, administered after a time interval, that induces systemic and/or tumor-specific inflammation in the subject.
CPC Classifications
A61K 39/001102 A61K 9/0019 A61K 35/17 A61K 39/385 A61K 40/11 A61K 40/31 A61K 47/60 A61P 35/00 C07K 14/70517 C12N 15/86 A61K 2039/54 A61K 2039/545 A61K 2039/572 A61K 2039/6031 A61K 2039/627 C12N 2710/10334
Filing Date
2025-04-18
Application No.
19183635
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.